MedTrace Logo

Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides

NCT00985140 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2017-06-02

Study results available
· View outcomes & findings →

Summary

To examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gy) in patients who have mycosis fungoides (MF) staged as IB to IIIA.

Conditions

  • Mycosis Fungoides
  • Lymphomas: Non-Hodgkin
  • Lymphomas: Non-Hodgkin Peripheral T-Cell
  • Lymphomas: Non-Hodgkin Cutaneous Lymphoma

Interventions

RADIATION

Total Skin Electron Beam Therapy (TSEBT)

The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.

Sponsors & Collaborators

Principal Investigators

  • Richard T. Hoppe · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985140 on ClinicalTrials.gov